of Iloilo City 60% . Majority received prior BCG vaccination 70% . As to bacteriological status all were clinically diagnosed 100%. Location of Extrapulmonary TB was mostly in the cervical neck area presenting as lymphadenitis in 60% of cases followed by retinitis 14 % and perianal mass = 1 , inguinal mass = 1 and Gastrointestinal TB = 1. Most received TB Disease treatment regimen 2 HRZE and 4 HR in 78% cases. All were Genexpert negative. As to outcome 86% completed treatment, 1 died and 1 was lost to follow up.
Genexpert negative. As to outcome 86% completed treatment, 1 died and 1 was lost to follow up.
Conclusion:
Incidence of patients with EPTB and HIV is increasing.
Thus there should be more public awareness regarding the various presentation of EPTB especially in HIV patients young adult groups aged 19-39. But conventional polymerase chain reaction (PCR) used to identify mycobacterial species does not distinguish between M. tuberculosis and M. bovis BCG.
Methods: Identification was carried out using PCR and PCRrestriction fragment length polymorphism for the detected group of M. tuberculosis, and it was confirmed that it was M. bovis BCG.
Results: We directly identified M. bovis BCG genome.
See graphics.
Conclusion: By identifying that it is M. bovis BCG, we succeeded in treating tuberculous spondylitis with only internal treatment without surgical treatment.
An appropriate treatment can be examined by diagnosis using this PCR method. Background and Aims: Tuberculosis is a serious global public health issue, with the emergence of drug resistant TB (DR-TB) it poses an even greater risk. In order to curb this issue, World Health Organization (WHO) has suggested the usage of GeneXpert MTB/RIF assay in high risk patients. The objective of this study is to analyze the performance of GeneXpert assay in a "real world" setting in different types of sample.
Methods: All GeneXpert testing done in 2017 were examined and checked against the gold standard culture and drug sensitivity tests (DST) which were sent together with GeneXpert to ensure consistency of sample collection. Results were analyzed using SPSS ® Ver24 CrossTabulation method.
Results: 120 samples were sent in 2017; 2 samples were rejected; 4 samples' results were missing. 23 results were excluded due to no DST were sent. There were 74 pulmonary and 17 extrapulmonary samples. GeneXpert result for 28 pulmonary samples were positive for MTB while none were positive from extrapulmonary group. There were 2 false positive and 2 false negative pulmonary samples. All extrapulmonary DST results were negative except for one pleural fluid sample returned as MTB. Therefore, sensitivity of GeneXpert assay for pulmonary samples was 95.7% while specificity was 92.9%. Sensitivity of GeneXpert assay for extrapulmonary samples was 100% while specificity was 100%. Furthermore, our findings were also analyzed for rifampicin resistance, 7 GeneXpert/RIF results were found to have rifampicin resistance, but only 2 of these samples' cultures (or 28%) returned as MDR-TB.
Conclusion: Based on our findings, we conclude that GeneXpert is highly sensitive and specific in detecting susceptible and DR-TB especially rifampicin resistance. Rifampicin resistance has been traditionally regarded as a surrogate marker for MDR-TB.
(1) A study quoted 90% of all clinical isolates with RR-TB also positive for isoniazid resistance.
(2) (3) However, our findings failed to show this pattern. Results: Results of 4282 subjects were analyzed for LTBI, 814 males and 3,468 females. The mean age was 37.6 years. The IGRA positive rate was 62.3%, 74.4% for males and 59.6% for females (P = 0.0000) when indeterminate results were excluded. By age group, 38% of teens were positive and 58% were in their 20s. In multivariate analysis, males (aOR; 1.92, 95% CI; 1.57-2.34), age, TB related lesion on chest X-ray (aOR; 5.54, 95% OR; 4.07-7.53) were associated with the rate. Preven 
